vs
GRAHAM CORP（GHM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GRAHAM CORP的季度营收约是REGENXBIO Inc.的1.9倍（$56.7M vs $30.3M），GRAHAM CORP净利率更高（5.0% vs -221.3%，领先226.4%），REGENXBIO Inc.同比增速更快（43.0% vs 20.5%），GRAHAM CORP自由现金流更多（$2.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.5%）
格雷厄姆控股公司是一家多元化的美国控股集团，总部位于弗吉尼亚州阿灵顿县，在特拉华州注册成立，该集团曾是《华盛顿邮报》与《新闻周刊》杂志的所有者。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GHM vs RGNX — 直观对比
营收规模更大
GHM
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出22.5%
20.5%
净利率更高
GHM
高出226.4%
-221.3%
自由现金流更多
GHM
多$55.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
7.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.7M | $30.3M |
| 净利润 | $2.8M | $-67.1M |
| 毛利率 | 23.8% | — |
| 营业利润率 | 5.5% | -190.0% |
| 净利率 | 5.0% | -221.3% |
| 营收同比 | 20.5% | 43.0% |
| 净利润同比 | 79.2% | -31.2% |
| 每股收益（稀释后） | $0.25 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHMRGNX
| Q4 25 | $56.7M | $30.3M | ||
| Q3 25 | $66.0M | $29.7M | ||
| Q2 25 | $55.5M | $21.4M | ||
| Q1 25 | $59.3M | $89.0M | ||
| Q4 24 | $47.0M | $21.2M | ||
| Q3 24 | $53.6M | $24.2M | ||
| Q2 24 | $50.0M | $22.3M | ||
| Q1 24 | $49.1M | $15.6M |
净利润GHMRGNX
| Q4 25 | $2.8M | $-67.1M | ||
| Q3 25 | $3.1M | $-61.9M | ||
| Q2 25 | $4.6M | $-70.9M | ||
| Q1 25 | $4.4M | $6.1M | ||
| Q4 24 | $1.6M | $-51.2M | ||
| Q3 24 | $3.3M | $-59.6M | ||
| Q2 24 | $3.0M | $-53.0M | ||
| Q1 24 | $1.3M | $-63.3M |
毛利率GHMRGNX
| Q4 25 | 23.8% | — | ||
| Q3 25 | 21.7% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 27.0% | — | ||
| Q4 24 | 24.8% | 70.2% | ||
| Q3 24 | 23.9% | 48.8% | ||
| Q2 24 | 24.8% | 52.5% | ||
| Q1 24 | 25.9% | 72.6% |
营业利润率GHMRGNX
| Q4 25 | 5.5% | -190.0% | ||
| Q3 25 | 6.5% | -176.3% | ||
| Q2 25 | 8.9% | -296.3% | ||
| Q1 25 | 9.3% | 13.6% | ||
| Q4 24 | 4.7% | -242.1% | ||
| Q3 24 | 7.9% | -256.6% | ||
| Q2 24 | 6.5% | -251.3% | ||
| Q1 24 | 3.1% | -408.8% |
净利率GHMRGNX
| Q4 25 | 5.0% | -221.3% | ||
| Q3 25 | 4.7% | -208.3% | ||
| Q2 25 | 8.3% | -331.8% | ||
| Q1 25 | 7.4% | 6.8% | ||
| Q4 24 | 3.4% | -241.3% | ||
| Q3 24 | 6.1% | -246.3% | ||
| Q2 24 | 5.9% | -237.7% | ||
| Q1 24 | 2.7% | -405.4% |
每股收益（稀释后）GHMRGNX
| Q4 25 | $0.25 | $-1.30 | ||
| Q3 25 | $0.28 | $-1.20 | ||
| Q2 25 | $0.42 | $-1.38 | ||
| Q1 25 | $0.40 | $0.12 | ||
| Q4 24 | $0.14 | $-0.99 | ||
| Q3 24 | $0.30 | $-1.17 | ||
| Q2 24 | $0.27 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $131.3M | $102.7M |
| 总资产 | $292.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHMRGNX
| Q4 25 | $22.3M | $230.1M | ||
| Q3 25 | $20.6M | $274.2M | ||
| Q2 25 | $10.8M | $323.3M | ||
| Q1 25 | $21.6M | $267.9M | ||
| Q4 24 | $30.0M | $234.7M | ||
| Q3 24 | $32.3M | $255.5M | ||
| Q2 24 | $21.6M | $290.4M | ||
| Q1 24 | $16.9M | $338.7M |
股东权益GHMRGNX
| Q4 25 | $131.3M | $102.7M | ||
| Q3 25 | $127.6M | $161.5M | ||
| Q2 25 | $123.4M | $213.7M | ||
| Q1 25 | $119.6M | $274.2M | ||
| Q4 24 | $114.4M | $259.7M | ||
| Q3 24 | $112.5M | $301.4M | ||
| Q2 24 | $108.2M | $348.3M | ||
| Q1 24 | $105.6M | $390.7M |
总资产GHMRGNX
| Q4 25 | $292.9M | $453.0M | ||
| Q3 25 | $287.0M | $525.2M | ||
| Q2 25 | $252.3M | $581.0M | ||
| Q1 25 | $264.1M | $490.9M | ||
| Q4 24 | $264.3M | $466.0M | ||
| Q3 24 | $249.5M | $519.1M | ||
| Q2 24 | $244.2M | $569.4M | ||
| Q1 24 | $233.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $2.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 4.3% | -174.0% |
| 资本支出强度资本支出/营收 | 4.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.67× | — |
| 过去12个月自由现金流最近4个季度 | $-6.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GHMRGNX
| Q4 25 | $4.8M | $-52.3M | ||
| Q3 25 | $13.6M | $-56.0M | ||
| Q2 25 | $-2.3M | $-49.3M | ||
| Q1 25 | $-3.6M | $33.6M | ||
| Q4 24 | $5.2M | $-31.6M | ||
| Q3 24 | $13.9M | $-40.5M | ||
| Q2 24 | $8.7M | $-45.5M | ||
| Q1 24 | $8.6M | $-55.5M |
自由现金流GHMRGNX
| Q4 25 | $2.4M | $-52.8M | ||
| Q3 25 | $9.4M | $-56.5M | ||
| Q2 25 | $-9.3M | $-49.7M | ||
| Q1 25 | $-8.7M | $32.6M | ||
| Q4 24 | $-2.1M | $-32.7M | ||
| Q3 24 | $10.4M | $-40.9M | ||
| Q2 24 | $5.7M | $-46.0M | ||
| Q1 24 | $4.6M | $-56.0M |
自由现金流率GHMRGNX
| Q4 25 | 4.3% | -174.0% | ||
| Q3 25 | 14.3% | -189.9% | ||
| Q2 25 | -16.7% | -232.8% | ||
| Q1 25 | -14.7% | 36.6% | ||
| Q4 24 | -4.5% | -154.2% | ||
| Q3 24 | 19.5% | -168.9% | ||
| Q2 24 | 11.5% | -206.2% | ||
| Q1 24 | 9.4% | -358.5% |
资本支出强度GHMRGNX
| Q4 25 | 4.1% | 1.7% | ||
| Q3 25 | 6.3% | 1.7% | ||
| Q2 25 | 12.6% | 1.8% | ||
| Q1 25 | 8.7% | 1.2% | ||
| Q4 24 | 15.6% | 5.1% | ||
| Q3 24 | 6.5% | 1.3% | ||
| Q2 24 | 6.0% | 2.1% | ||
| Q1 24 | 8.2% | 3.6% |
现金转化率GHMRGNX
| Q4 25 | 1.67× | — | ||
| Q3 25 | 4.40× | — | ||
| Q2 25 | -0.49× | — | ||
| Q1 25 | -0.81× | 5.53× | ||
| Q4 24 | 3.29× | — | ||
| Q3 24 | 4.25× | — | ||
| Q2 24 | 2.94× | — | ||
| Q1 24 | 6.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GHM
| Defense | $35.3M | 62% |
| Energy And Process | $18.3M | 32% |
| Space | $3.1M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
